Join
Live feed
·
PRReleasevia Quantisnow
HOOKIPA Pharma Inc. logo

HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform

ByQuantisnow·Wall Street's wire, on your screen.
HOOK· HOOKIPA Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HOOK (HOOKIPA Pharma Inc.) and more on Quantisnow.